NeoDynamics presents preclinical results today
Dr. Stefan Paepke presents an abstract on preclinical results with NeoDynamics’ innovative biopsy system NeoNavia at the St Gallen International Breast Cancer Conference 2021, which begins in Vienna today. The results show that tissue samples taken with all of NeoNavia’s three needle types provide significantly larger tissue samples than what today’s gold standard technologies achieve.
The weight of the tissue samples taken with NeoNavia’s needles was 299 percent higher with the FlexiPulse needle than with today’s gold standard, 37 percent higher with CorePulse and 12 percent higher with VacuPulse. The choice of needle type is mainly made based on the tumor’s characteristics and location, where FlexiPulse is used in particularly difficult location such as in the axilla.
Dr. Stefan Paepke is chief physician at the University Hospital r.d. Isar at the Technical University of Munich and is a spokesperson for the German working group for minimally invasive methods, AG mimi and member of NeoDynamics’ advisory board.
Presentation on Redeye at 1 p.m.
Due to the presentation at the congress, NeoDynamics and Redeye are arranging a parallell digital presentation for the financial markets today, March 17 at 13.00-14.00. At this presentation, CEO Anna Eriksrud and Dr Kai-Uwe Schässburger, Head of Clinical Development & Medical Affairs, will present the preclinical results and also comment on the launch of the product. The presentation is followed by a question and answer session led by Redeye’s analyst Oskar Bergman.
Registration for the presentation is made via the following link: https://www.lyyti.in/Strategy_Update_NeoDynamics_9010
The presentation will be held in English.
The abstract will also be published in the scientific journal The Breast.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden.
About NeoNavia
NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
